Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity

Summary

Due to variability in the one-stage clotting assay, the performance of new factor IX (FIX) products should be assessed in this assay. The objective of this field study was to evaluate the accuracy of measuring recombinant FIX Fc fusion protein (rFIXFc) activity in clinical haemostasis laboratories using the one-stage clotting assay. Human haemophilic donor plasma was spiked with rFIXFc or BeneFIX^® at 0.80, 0.20, or 0.05 IU/ml based on label potency. Laboratories tested blinded samples using their routine one-stage assay and in-house FIX plasma standard. The mean spike recoveries for BeneFIX (n=30 laboratories) were 121 %, 144 %, and 168 % of expected at nominal 0.80, 0.20, and 0.05 IU/ml concentrations, respectively. Corresponding rFIXFc spike recoveries were 88 %, 107 %, and 132 % of expected, respectively. All BeneFIX concentrations were consistently overestimated by most laboratories. rFIXFc activity was reagent-dependent; ellagic acid and silica gave higher values than kaolin, which underestimated rFIXFc. BeneFIX demonstrated significantly reduced chromogenic assay activity relative to one-stage assay results and nominal activity, while rFIXFc activity was close to nominal activity at three concentrations with better dilution linearity than the typical one-stage assay. In conclusion, laboratory- and reagent-specific assay variabilities were revealed, with progressively higher variability at lower FIX concentrations. Non-parallelism against the FIX plasma standard was observed in all one-stage assays with rFIXFc and BeneFIX, leading to significant overestimation of FIX activity at lower levels and generally high inter-laboratory variability. Compared to the accuracy currently achieved in clinical laboratories when measuring other rFIX products, most laboratories measured rFIXFc activity with acceptable accuracy and reliability using routine one-stage assay methods and commercially available plasma standards.

Keywords

Activated partial thromboplastin time (aPTT) - coagulation factor IX - haemophilia B - coagulation tests - blood - standardisation

• References

• 1 Coppola A, Di CM, Di Minno MN. et al. Treatment of hemophilia: a review of current advances and ongoing issues. J Blood Med 2010; 1: 183-195.
• 2 Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. J Lab Clin Med 1953; 41: 637-647.
• 3 Ingerslev J. Laboratory assays in hemophilia. In: Textbook of Hemophilia. Wiley-Blackwell; 2010
• 4 Barrowcliffe TW. Insights from factor IX activation studies with chromogenic assays: implications of disparate product results. Haemophilia 2010; 16 (Suppl. 06) 9-12.
• 5 Pouplard C, Trossaert M, LE QA. et al. Influence of source of phospholipids for aPTT-based factor IX assays and potential consequences for the diagnosis of mild haemophilia B. Haemophilia 2009; 15: 365-368.
• 6 Shetty S, Ghosh K, Mohanty D. Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer. Blood Coagul Fibrinolysis 2003; 14: 493-497.
• 7 Kohler M, Seifried E, Hellstern P. et al. In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients. The influence of reagents and standards. Blut 1988; 57: 341-345.
• 8 Shima M, Matsumoto T, Fukuda K. et al. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C). Thromb Hae-most 2002; 87: 436-441.
• 9 Raut S, Hubbard AR. International reference standards in coagulation. Biologicals 2010; 38: 423-429.
• 10 Collins PW, Fischer K, Morfini M. et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
• 11 Hubbard AR, Dodt J, Lee T. et al. Recommendations on the potency labelling of factor VIII and factor IX concentrates. J Thromb Haemost 2013; 11: 988-989.
• 12 Lissitchkov T, Matysiak M, Zavilska K. et al. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine) and a recombinant factor IX (BeneFIX) in patients with severe haemophilia B. Haemophilia 2013; 19: 674-678.
• 13 Lambert T, Recht M, Valentino LA. et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007; 13: 233-243.
• 14 Roth DA, Kessler CM, Pasi KJ. et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-3606.
• 15 Powell JS, Pasi J, Ragni MV. et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369: 2313-2323.
• 16 Huang C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol 2009; 20: 692-699.
• 17 Kimchi-Sarfaty C, Schiller T, Hamasaki-Katagiri N. et al. Building better drugs: developing and regulating engineered therapeutic proteins. Trends Pharmacol Sci 2013; 34: 534-548.
• 18 Rath T, Baker K, Dumont JA. et al. Fc-fusion proteins and FcRn: structural insights for longer lasting and more effective therapeutics. Crit Rev Biotechnol. 2013 Epub ahead of print.
• 19 Dumont JA, Low SC, Peters RT. et al. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 2006; 20: 151-160.
• 20 Peters RT, Low SC, Kamphaus GD. et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115: 2057-2064.
• 21 Valentino LA. Recombinant FIXFc: a novel therapy for the royal disease?. Expert Opin Biol Ther 2011; 11: 1361-1368.
• 22 Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715-725.
• 23 Zhang M, Lu Q, Mei B. et al. Detection of galactose-alpha-1,3-galactose (a-Gal) and N-glycolylneuraminic acid (NGNA) in recombinant and plasma derived FIX products. J Thromb Haemost 2013; 11: 320. Abstract PA 1.12–4.
• 24 Toby G, Peters RT, Bitonti AJ. Biochemical characterization of factor IX-Fc monomer. J Thromb Haemost 2009; 7: 134.
• 25 Gray E, Pickering W, Hockley J. et al. Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards. Pharmeuropa Bio 2008; 2008: 19-30.
• 26 Srivastava A, Brewer AK, Mauser-Bunschoten EP. et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-e47.
• 27 Kitchen S, Signer K, Key N. Current laboratory practices in the management of haemophilia: a global assessment. Haemophilia 2013; 19: 50-51.
• 28 Ingerslev J, Jankowski MA, Weston SB. et al. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr factor VIII:C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost 2004; 2: 623-628.
• 29 Viuff D, Barrowcliffe T, Saugstrup T. et al. International comparative field study of N8 evaluating factor VIII assay performance. Haemophilia 2011; 17: 695-702.
• 30 Gu JM, Ramsey P, Evans V. et al. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94–9027) for haemophilia A. Haemophilia 2014; 20: 593-600.
• 31 ALPROLIX™ [Coagulation Factor IX (Recombinant), FC Fusion Protein [package insert]. Biogen Idec, Inc.. Cambridge, MA: March 2014